TY  - JOUR
AU  - Kronenberg, T.
TI  - Erstellung einer Input-Output-Tabelle für Mecklenburg-Vorpommern
JO  - Wirtschafts- und sozialstatistisches Archiv
VL  - 4
SN  - 1863-8155
CY  - Berlin
PB  - Springer
M1  - PreJuSER-11439
SP  - 223 - 248
PY  - 2010
N1  - Record converted from VDB: 12.11.2012
AB  - The IRESSA Survival Evaluation in Lung Cancer (ISEL) phase III study compared the efficacy of gefitinib (IRESSA) versus placebo in patients with refractory advanced non-small cell lung cancer (NSCLC). Although a statistically significant difference in survival was not seen between gefitinib and placebo in the overall ISEL population, preplanned subset analyses demonstrated a significant survival benefit in patients who had never smoked and in patients of Asian origin.In ISEL, 1692 patients who were refractory to or intolerant of their latest chemotherapy were randomized to receive either gefitinib (250 mg/day) or placebo, plus best supportive care. Preplanned subgroup analyses included an assessment of patients who were of Asian origin (n = 342).Two hundred thirty-five patients of Asian origin received gefitinib, and 107 received placebo. In these patients, treatment with gefitinib significantly improved survival compared with placebo (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.48, 0.91; p = 0.010; median survival, 9.5 versus 5.5 months). Patients of Asian origin also experienced statistically significant improvements in time to treatment failure with gefitinib compared with placebo (HR, 0.69; 95% CI, 0.52, 0.91; p = 0.0084; 4.4 versus 2.2 months), and objective response rates were higher with gefitinib than with placebo (12 versus 2%). Gefitinib was generally well tolerated in patients of Asian origin, with rash and diarrhea being the most common adverse events. No unexpected adverse events were observed.Treatment with gefitinib was associated with a significant improvement in survival in a subgroup of patients of Asian origin with previously treated refractory advanced NSCLC.
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents: adverse effects
KW  - Antineoplastic Agents: therapeutic use
KW  - Asian Continental Ancestry Group
KW  - Carcinoma, Non-Small-Cell Lung: drug therapy
KW  - Carcinoma, Non-Small-Cell Lung: ethnology
KW  - Carcinoma, Non-Small-Cell Lung: mortality
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Lung Neoplasms: drug therapy
KW  - Lung Neoplasms: ethnology
KW  - Lung Neoplasms: mortality
KW  - Male
KW  - Middle Aged
KW  - Protein Kinase Inhibitors: adverse effects
KW  - Protein Kinase Inhibitors: therapeutic use
KW  - Quinazolines: adverse effects
KW  - Quinazolines: therapeutic use
KW  - Receptor, Epidermal Growth Factor: antagonists & inhibitors
KW  - Survival Rate
KW  - Antineoplastic Agents (NLM Chemicals)
KW  - Protein Kinase Inhibitors (NLM Chemicals)
KW  - Quinazolines (NLM Chemicals)
KW  - gefitinib (NLM Chemicals)
KW  - Receptor, Epidermal Growth Factor (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:17409969
DO  - DOI:10.1007/s11943-010-0084-9
UR  - https://juser.fz-juelich.de/record/11439
ER  -